Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2020-08-04 AGM Information
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Date of AGM 1 page 326.9KB
AGM Information Classification · 95% confidence The document is a short announcement dated 5 August 2020 from Regeneus Ltd regarding the date of its 2020 Annual General Meeting and the closing date for director nominations. It references the ASX Listing Rule 3.13.1 and provides procedural details about the AGM but does not contain any financial data, report content, or detailed meeting materials. It is an announcement about the AGM logistics rather than the AGM materials themselves. The document length is only 990 characters, indicating it is a brief notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, or announcements related to the AGM. Since this is about the AGM date and nominations, it is best classified as AGM Information (AGM-R).
2020-08-04 English
Appendix 4C - Quarterly 7 pages 309.1KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 31 July 2020, titled 'Quarterly Cashflow report – Period ending 30 June 2020'. It includes detailed financial data such as consolidated statements of cash flows for the quarter and year to date, reconciliation of cash and cash equivalents, financing facilities, and estimated cash available for future operating activities. The document references compliance with ASX Listing Rule 4.7B and includes an Appendix 4C quarterly cash flow report, which is a regulatory requirement for quarterly reporting by entities listed on the ASX. The content is comprehensive and contains actual financial statements and substantive financial data for a period shorter than a full fiscal year (quarterly). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a report publication announcement, but a full quarterly financial report with operational and financial details. Q4 2020
2020-07-30 English
Progenza OA Kyocera negotiations update 1 page 111.
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 28 July 2020 providing an update on the negotiation status of a commercial licence agreement between Regeneus Ltd and Kyocera Corporation. It discusses the extension of exclusivity for negotiation rights and states that Regeneus will update the market in due course. There is no financial data, no detailed report, no regulatory certification, no voting results, no management or board changes, and no legal proceedings. The document is a brief corporate update on a licensing negotiation, which fits best under a general regulatory announcement category. The document length is short (2006 characters), and it is not a report or presentation but an announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-07-27 English
Director Resignation 1 page 120.3KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 June 2020 regarding a change in the board of directors of Regeneus Ltd. It specifically announces the resignation of a non-executive director and includes statements from the chairman thanking the director. There is no financial data, no mention of a report or filing, and the content is focused solely on management/board changes. The document length is short (1540 characters), and it is clearly an announcement of a board change rather than a full report or other filing type. Therefore, the appropriate classification is Board/Management Information (MANG).
2020-06-03 English
Appendix 3Z - Final Director's Interest Notice 2 pages 121.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shareholdings and interests in contracts. The document length is 2398 characters, which is relatively short and focused solely on director share interests. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions or holdings by company directors. There is no indication of financial results, management discussion, or other report types. Therefore, the document is best classified as a Director's Dealing filing.
2020-06-03 English
Kyocera completes Progenza Due Diligence 1 page 124
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 May 2020 from Regeneus Ltd regarding the completion of due diligence by Kyocera on a stem cell technology platform. It discusses a milestone payment and negotiation rights under a Memorandum of Understanding. The content is an update on a financing or partnership milestone rather than a financial report, regulatory filing, or management report. The document length is short (1797 characters) and it is clearly an announcement of a business development related to financing/licensing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-05-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.